QNTM — Quantum Biopharma Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1771885 ·
Ontario, Canada
Last close
$3.11
Market Cap
$20.00M
52W High
$16.36
52W Low
$2.07
ADV30
188,632
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -2,281,086 | -3,252,967 | 14,391,885 | 3,647,072 | 8,297,670 |
| Mar 2026 | 0 | — | -2,909,492 | -13,560,299 | 14,926,075 | 4,341,908 | 16,345,974 |
| Dec 2025 | 0 | — | -2,359,801 | -3,026,467 | 11,160,909 | 1,905,357 | 6,058,294 |
| Sep 2025 | 0 | — | -4,658,195 | -5,319,029 | 14,153,228 | 445,944 | 6,646,480 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-5,644,918
Investing CF
$-3,495,520
Financing CF
$9,964,033
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-11.07
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-211,846,469
Inventory
$51,468
Receivables
$208,524
ST Investments
$222,906
EBIT TTM
$-31,657,316
Pretax Income TTM
$-31,970,523
Interest Exp TTM
$313,207
Analysts
1
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -15,317,409 | -26,175,286 | 11,160,909 | 6,058,294 | 6,924,475 | -8,237,012 |
| Dec 2024 | 0 | -15,884,034 | -14,202,724 | 17,119,224 | 6,678,992 | 11,480,538 | -6,876,479 |
| Dec 2023 | 0 | -19,570,114 | -17,902,179 | 17,474,828 | 4,565,566 | 13,236,763 | -10,827,264 |
| Dec 2022 | 0 | -27,429,611 | -23,606,828 | 38,410,656 | 7,868,436 | 30,542,220 | -28,333,273 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-7.80
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RMHI | Retrieve Medical Holdings, Inc. | $20.42M | $0.69 | — |
| PBM | PSYENCE BIOMEDICAL LTD. | $19.53M | $5.12 | — |
| COCP | Cocrystal Pharma, Inc. | $20.61M | $1.07 | — |
| UPC | Universe Pharmaceuticals INC | $20.93M | $4.18 | — |
| PVCT | PROVECTUS BIOPHARMACEUTICALS, INC. | $21.01M | $0.05 | — |
News headlines (Yahoo Finance, 1h cache)
World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum B
2026-10-08 12:00 · Yahoo
Quantum BioPharma (QNTM) Enlists Thermo Fisher's Clinical Research Business to Launch Phase 2 Lucid-MS Trial
2026-10-07 19:30 · Yahoo
Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis
2026-10-06 10:00 · Yahoo
IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.
2026-09-30 12:00 · Yahoo
Quantum BioPharma (QNTM) Receives FDA Green Light to Move Lucid-MS Into Phase 2 Testing
2026-09-25 19:00 · Yahoo
Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO
2026-09-24 12:00 · Yahoo
Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target
2026-09-17 12:00 · Yahoo
Quantum BioPharma (QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth Summit
2026-09-15 19:30 · Yahoo
Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto
2026-09-15 12:00 · Yahoo
Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials
2026-09-11 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.